PRITHVIRAJ BOSE

Assistant Professor

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Prithviraj Bose is an Assistant Professor at the University of Texas MD Anderson Cancer Center in the United States. His research focuses on therapeutic approaches for myeloproliferative neoplasms, particularly myelofibrosis and acute myeloid leukemia. He has contributed extensively to recent literature on emerging therapies and outcomes for these conditions, highlighting the efficacy of various treatment combinations and protocols.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (13)

Vikas Gupta

CANADA

View details

Srdan Verstovsek

UNITED STATES

View details

Jayastu Senapati

Assistant professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Zeev Estrov

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Aaron Gerds

Assitant Professor

Cleveland Clinic

UNITED STATES

View details

Teny M John

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Warren Fiskus

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Philip A Thompson

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Elias J. Jabbour

UNITED STATES

View details

Courtney D. DiNardo

UNITED STATES

View details

Christine Peterson

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Musa Yilmaz

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Naval G. Daver

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

PRITHVIRAJ BOSE

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Contemporary outcomes of octa‐nonagenarians with newly diagnosed acute myeloid leukemia

Emerging Therapeutic Approaches for Anemia in Myelofibrosis

Ruxolitinib Meets a Forgotten Malady

Momelotinib – a tale of trials, tribulations, transfusion independence, and triumph

Polycythaemia vera

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis

Ruxolitinib for myelofibrosis: The earlier, the better?

Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments

Momelotinib: an emerging treatment for myelofibrosis patients with anemia

Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis

STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells

Improved survival of patients with myelofibrosis in the last decade: Single‐center experience

Disease Modification in Myelofibrosis: An Elusive Goal?

Novel strategies for challenging scenarios encountered in managing myelofibrosis

Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

Collaborators (13)

Vikas Gupta

Srdan Verstovsek

Jayastu Senapati

Zeev Estrov

Aaron Gerds

Teny M John

Warren Fiskus

Philip A Thompson

Elias J. Jabbour

Courtney D. DiNardo

Christine Peterson

Musa Yilmaz

Naval G. Daver

Make your next move.